---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-26-000003"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2026-01-09T23:59:59+00:00"
generated_at: "2026-05-16T11:04:22.844354+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Keros Therapeutics corporate presentation highlights Phase 2 data and cash runway into 2028

## Summary
- Phase 2 KER-050 in lower-risk MDS: 45% RBC transfusion independence at 24 weeks (ASH Dec 2025).
- Phase 2 KER-012 in PAH met primary endpoint: 35m improvement in 6-min walk distance at 24 weeks.
- Cash, equivalents and short-term investments of $367.4M as of Sep 30, 2025, funding operations into 2028.
- Upcoming milestones: KER-050 higher-risk MDS data mid-2026; KER-012 HFpEF trial start H1 2026; KER-065 Phase 1 data H1 2026.
- No new financing, leadership changes, or material agreements disclosed in the update.

## SEC filing metadata
- accession: 0001664710-26-000003
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2026-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471026000003/0001664710-26-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471026000003/kros-20260109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-26-000003
- JSON: https://secwatch.observer/filing/0001664710-26-000003.json
- Plain text: https://secwatch.observer/filing/0001664710-26-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.